Seguir
Patrick C. Gedeon, M.D., Ph.D.
Patrick C. Gedeon, M.D., Ph.D.
Mass General Brigham and Dana-Farber Cancer Institute
Dirección de correo verificada de mgb.org - Página principal
Título
Citado por
Citado por
Año
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma
BD Choi, CT Kuan, M Cai, GE Archer, DA Mitchell, PC Gedeon, ...
Proceedings of the National Academy of Sciences 110 (1), 270-275, 2013
1692013
Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma
BD Choi, CM Suryadevara, PC Gedeon, JE Herndon II, L Sanchez-Perez, ...
Journal of Clinical Neuroscience 21 (1), 189-190, 2014
124*2014
Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma
EA Reap, CM Suryadevara, KA Batich, L Sanchez-Perez, GE Archer, ...
Cancer research 78 (1), 256-264, 2018
1002018
Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
CM Suryadevara, R Desai, ML Abel, KA Riccione, KA Batich, SH Shen, ...
OncoImmunology 7 (6), e1434464, 2018
882018
Are BiTEs the ‘missing link’ in cancer therapy?
CM Suryadevara, PC Gedeon, L Sanchez-Perez, T Verla, ...
OncoImmunology 4 (6), e1008339, 2015
822015
Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody
BD Choi, PC Gedeon, JE Herndon, GE Archer, EA Reap, ...
Cancer Immunology Research 1 (3), 163-167, 2013
77*2013
Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts
CM Suryadevara, R Desai, SH Farber, BD Choi, AM Swartz, SH Shen, ...
Clinical Cancer Research 25 (1), 358-368, 2019
592019
Molecular dynamics of leucine and dopamine transporter proteins in a model cell membrane lipid bilayer
PC Gedeon, M Indarte, CK Surratt, JD Madura
Proteins: Structure, Function, and Bioinformatics 78 (4), 797-811, 2010
472010
A rationally designed fully human EGFRvIII:CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma
PC Gedeon, TH Schaller, SK Chitneni, BD Choi, CT Kuan, ...
Clinical Cancer Research 24 (15), 3611-3631, 2018
432018
Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
BD Choi, PC Gedeon, L Sanchez-Perez, DD Bigner, JH Sampson
OncoImmunology 2 (12), e26757, 2013
432013
Epidermal growth factor receptor and variant III targeted immunotherapy
KL Congdon, PC Gedeon, CM Suryadevara, HG Caruso, LJN Cooper, ...
Neuro-oncology 16 (suppl_8), viii20-viii25, 2014
422014
LeuT conformational sampling utilizing accelerated molecular dynamics and principal component analysis
JR Thomas, PC Gedeon, BJ Grant, JD Madura
Biophysical Journal 103 (1), L1-L3, 2012
332012
Accelerated molecular dynamics and protein conformational change: a theoretical and practical guide using a membrane embedded model neurotransmitter transporter
PC Gedeon, JR Thomas, JD Madura
Methods in Molecular Biology 1215, 253-287, 2015
312015
An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma
PC Gedeon, BD Choi, TR Hodges, DA Mitchell, DD Bigner, JH Sampson
Expert Review of Clinical Pharmacology 6 (4), 375-386, 2013
312013
Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic
PC Gedeon, BD Choi, JH Sampson, DD Bigner
Drugs of the Future 38 (3), 147-155, 2013
302013
First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach
TH Schaller, DJ Snyder, I Spasojevic, PC Gedeon, L Sanchez-Perez, ...
Journal for Immunotherapy of Cancer 8 (1), e000213, 2020
232020
Antibody-Based Immunotherapy for Malignant Glioma
PC Gedeon, KA Riccione, PE Fecci, JH Sampson
Seminars in Oncology 41 (4), 496-510, 2014
182014
Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook
PC Gedeon, CD Champion, KE Rhodin, K Woroniecka, HR Kemeny, ...
Expert Review of Clinical Pharmacology 13 (10), 1147-1158, 2020
102020
Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis
BD Choi, PC Gedeon, CT Kuan, L Sanchez-Perez, GE Archer, DD Bigner, ...
Journal of immunological methods 395 (1-2), 14-20, 2013
72013
GLP toxicology study of a fully-human T cell redirecting CD3: EGFRvIII binding immunotherapeutic bispecific antibody
PC Gedeon, MA Streicker, TH Schaller, GE Archer, MP Jokinen, ...
PloS one 15 (7), e0236374, 2020
62020
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20